Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Sponsor: Eli Lilly and Company
Summary
Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174). The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.
Official title: A Master Protocol for Open-Label Extension Studies to Evaluate the Long-Term Safety and Tolerability of Interventions in Various Stages of Clinical Development in Participants With Amyotrophic Lateral Sclerosis
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-05-14
Completion Date
2029-06
Last Updated
2026-07-17
Healthy Volunteers
No
Conditions
Interventions
LY4256984
Administered IT
Locations (10)
UZ Leuven
Leuven, Belgium
University Hospital - London Health Sciences Centre
London, Canada
McGill University Health Centre
Montreal, Canada
Sunnybrook Research Institute
Toronto, Canada
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Universitätsmedizin Rostock
Rostock, Germany
Universitaetsklinikum Ulm
Ulm, Germany
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain